{"id":858669,"date":"2025-06-09T16:43:23","date_gmt":"2025-06-09T20:43:23","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/sana-biotechnology-announces-invited-oral-presentation-at-the-85th-annual-american-diabetes-association-scientific-sessions\/"},"modified":"2025-06-09T16:43:23","modified_gmt":"2025-06-09T20:43:23","slug":"sana-biotechnology-announces-invited-oral-presentation-at-the-85th-annual-american-diabetes-association-scientific-sessions","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/sana-biotechnology-announces-invited-oral-presentation-at-the-85th-annual-american-diabetes-association-scientific-sessions\/","title":{"rendered":"Sana Biotechnology Announces Invited Oral Presentation at the 85th Annual American Diabetes Association Scientific Sessions"},"content":{"rendered":"

\nPresentation to highlight updated six-month clinical results of a hypoimmune-modified primary pancreatic islet cell therapy for patients with type 1 diabetes
\n<\/h2>\n
\n

SEATTLE, June 09, 2025 (GLOBE NEWSWIRE) — Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced\u00a0an upcoming podium presentation highlighting ongoing clinical data from the investigator-sponsored, first-in-human study transplanting UP421, an allogeneic primary islet cell therapy engineered with Sana\u2019s hypoimmune (HIP) technology, into a patient with type 1 diabetes without the use of any immunosuppression. The presentation will be held during a joint American Diabetes Association (ADA)\/International Pancreas & Islet Transplant Association (IPITA) symposium at the 85th<\/sup> Annual ADA Scientific Sessions taking place June 20-23, 2025 in Chicago, IL.<\/p>\n

Presentation details:<\/p>\n\n\n\n\n\n\n\n
\n Symposium\u00a0Title:<\/strong>\n <\/td>\n\u00a0<\/td>\nJoint ADA\/IPITA Symposium: Outpacing the Immune System\u2014Sprinting Towards Immune Protection for Cell Replacement Therapy<\/td>\n<\/tr>\n
\n Presentation\u00a0Title:<\/strong>\n <\/td>\n\u00a0<\/td>\nHypoimmune Pancreatic Islet Transplantation in Adult Subjects with Type 1 Diabetes<\/td>\n<\/tr>\n
\n Presentation\u00a0Date:<\/strong>\n <\/td>\n\u00a0<\/td>\nMonday, June 23, 2025<\/td>\n<\/tr>\n
\n Presentation\u00a0Time:<\/strong>\n <\/td>\n\u00a0<\/td>\n9:00 \u2013 9:20 a.m. CT<\/td>\n<\/tr>\n
\n Location:<\/strong>\n <\/td>\n\u00a0<\/td>\nW192 A-C<\/td>\n<\/tr>\n
\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n<\/table>\n

\n About Sana<\/strong>\n <\/p>\n

Sana Biotechnology, Inc. is focused on creating and delivering engineered cells as medicines for patients. We share a vision of repairing and controlling genes, replacing missing or damaged cells, and making our therapies broadly available to patients. We are a passionate group of people working together to create an enduring company that changes how the world treats disease. Sana has operations in Seattle, WA, Cambridge, MA, South San Francisco, CA and Bothell, WA.<\/p>\n

\n Cautionary Note Regarding Forward-Looking Statements<\/strong>\n <\/p>\n

This press release contains forward-looking statements about Sana Biotechnology, Inc. (the \u201cCompany,\u201d \u201cwe,\u201d \u201cus,\u201d or \u201cour\u201d) within the meaning of the federal securities laws, including those related to the company\u2019s vision and expectations regarding participation in and the presentation at the 85th<\/sup> Annual American Diabetes Association Scientific Sessions, including the content of such presentation. All statements other than statements of historical facts contained in this press release, including, among others, statements regarding the Company\u2019s strategy, expectations, cash runway and future financial condition, future operations, and prospects, are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as \u201caim,\u201d \u201canticipate,\u201d \u201cassume,\u201d \u201cbelieve,\u201d \u201ccontemplate,\u201d \u201ccontinue,\u201d \u201ccould,\u201d \u201cdesign,\u201d \u201cdue,\u201d \u201cestimate,\u201d \u201cexpect,\u201d \u201cgoal,\u201d \u201cintend,\u201d \u201cmay,\u201d \u201cobjective,\u201d \u201cplan,\u201d \u201cpositioned,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cseek,\u201d \u201cshould,\u201d \u201ctarget,\u201d \u201cwill,\u201d \u201cwould,\u201d and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. The Company has based these forward-looking statements largely on its current expectations, estimates, forecasts and projections about future events and financial trends that it believes may affect its financial condition, results of operations, business strategy and financial needs. In light of the significant uncertainties in these forward-looking statements, you should not rely upon forward-looking statements as predictions of future events. These statements are subject to risks and uncertainties that could cause the actual results to vary materially, including, among others, the risks inherent in drug development such as those associated with the initiation, cost, timing, progress and results of the Company\u2019s current and future research and development programs, preclinical and clinical trials, as well as economic, market, and social disruptions. For a detailed discussion of the risk factors that could affect the Company\u2019s actual results, please refer to the risk factors identified in the Company\u2019s Securities and Exchange Commission reports, including but not limited to its Quarterly Report on Form 10-Q dated May 8, 2025. Except as required by law, the Company undertakes no obligation to update publicly any forward-looking statements for any reason.<\/p>\n

\n Investor Relations & Media:<\/strong>
\n
Nicole Keith
investor.relations@sana.com<\/a>
media@sana.com<\/a><\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

Presentation to highlight updated six-month clinical results of a hypoimmune-modified primary pancreatic islet cell therapy for patients with type 1 diabetes SEATTLE, June 09, 2025 (GLOBE NEWSWIRE) — Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced\u00a0an upcoming podium presentation highlighting ongoing clinical data from the investigator-sponsored, first-in-human study transplanting UP421, an allogeneic primary islet cell therapy engineered with Sana\u2019s hypoimmune (HIP) technology, into a patient with type 1 diabetes without the use of any immunosuppression. The presentation will be held during a joint American Diabetes Association (ADA)\/International Pancreas & Islet Transplant Association (IPITA) symposium at the 85th Annual ADA Scientific Sessions taking place June 20-23, 2025 in Chicago, IL. … <\/p>\n

Continue reading “Sana Biotechnology Announces Invited Oral Presentation at the 85th Annual American Diabetes Association Scientific Sessions”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-858669","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nSana Biotechnology Announces Invited Oral Presentation at the 85th Annual American Diabetes Association Scientific Sessions - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/sana-biotechnology-announces-invited-oral-presentation-at-the-85th-annual-american-diabetes-association-scientific-sessions\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sana Biotechnology Announces Invited Oral Presentation at the 85th Annual American Diabetes Association Scientific Sessions - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Presentation to highlight updated six-month clinical results of a hypoimmune-modified primary pancreatic islet cell therapy for patients with type 1 diabetes SEATTLE, June 09, 2025 (GLOBE NEWSWIRE) — Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced\u00a0an upcoming podium presentation highlighting ongoing clinical data from the investigator-sponsored, first-in-human study transplanting UP421, an allogeneic primary islet cell therapy engineered with Sana\u2019s hypoimmune (HIP) technology, into a patient with type 1 diabetes without the use of any immunosuppression. The presentation will be held during a joint American Diabetes Association (ADA)\/International Pancreas & Islet Transplant Association (IPITA) symposium at the 85th Annual ADA Scientific Sessions taking place June 20-23, 2025 in Chicago, IL. … Continue reading "Sana Biotechnology Announces Invited Oral Presentation at the 85th Annual American Diabetes Association Scientific Sessions"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/sana-biotechnology-announces-invited-oral-presentation-at-the-85th-annual-american-diabetes-association-scientific-sessions\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-06-09T20:43:23+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ2NTYyMyM2OTgyMzc3IzIyMDY2Mzc=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sana-biotechnology-announces-invited-oral-presentation-at-the-85th-annual-american-diabetes-association-scientific-sessions\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sana-biotechnology-announces-invited-oral-presentation-at-the-85th-annual-american-diabetes-association-scientific-sessions\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Sana Biotechnology Announces Invited Oral Presentation at the 85th Annual American Diabetes Association Scientific Sessions\",\"datePublished\":\"2025-06-09T20:43:23+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sana-biotechnology-announces-invited-oral-presentation-at-the-85th-annual-american-diabetes-association-scientific-sessions\\\/\"},\"wordCount\":607,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sana-biotechnology-announces-invited-oral-presentation-at-the-85th-annual-american-diabetes-association-scientific-sessions\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ2NTYyMyM2OTgyMzc3IzIyMDY2Mzc=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sana-biotechnology-announces-invited-oral-presentation-at-the-85th-annual-american-diabetes-association-scientific-sessions\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sana-biotechnology-announces-invited-oral-presentation-at-the-85th-annual-american-diabetes-association-scientific-sessions\\\/\",\"name\":\"Sana Biotechnology Announces Invited Oral Presentation at the 85th Annual American Diabetes Association Scientific Sessions - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sana-biotechnology-announces-invited-oral-presentation-at-the-85th-annual-american-diabetes-association-scientific-sessions\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sana-biotechnology-announces-invited-oral-presentation-at-the-85th-annual-american-diabetes-association-scientific-sessions\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ2NTYyMyM2OTgyMzc3IzIyMDY2Mzc=\",\"datePublished\":\"2025-06-09T20:43:23+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sana-biotechnology-announces-invited-oral-presentation-at-the-85th-annual-american-diabetes-association-scientific-sessions\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sana-biotechnology-announces-invited-oral-presentation-at-the-85th-annual-american-diabetes-association-scientific-sessions\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sana-biotechnology-announces-invited-oral-presentation-at-the-85th-annual-american-diabetes-association-scientific-sessions\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ2NTYyMyM2OTgyMzc3IzIyMDY2Mzc=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ2NTYyMyM2OTgyMzc3IzIyMDY2Mzc=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sana-biotechnology-announces-invited-oral-presentation-at-the-85th-annual-american-diabetes-association-scientific-sessions\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Sana Biotechnology Announces Invited Oral Presentation at the 85th Annual American Diabetes Association Scientific Sessions\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Sana Biotechnology Announces Invited Oral Presentation at the 85th Annual American Diabetes Association Scientific Sessions - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/sana-biotechnology-announces-invited-oral-presentation-at-the-85th-annual-american-diabetes-association-scientific-sessions\/","og_locale":"en_US","og_type":"article","og_title":"Sana Biotechnology Announces Invited Oral Presentation at the 85th Annual American Diabetes Association Scientific Sessions - Market Newsdesk","og_description":"Presentation to highlight updated six-month clinical results of a hypoimmune-modified primary pancreatic islet cell therapy for patients with type 1 diabetes SEATTLE, June 09, 2025 (GLOBE NEWSWIRE) — Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced\u00a0an upcoming podium presentation highlighting ongoing clinical data from the investigator-sponsored, first-in-human study transplanting UP421, an allogeneic primary islet cell therapy engineered with Sana\u2019s hypoimmune (HIP) technology, into a patient with type 1 diabetes without the use of any immunosuppression. The presentation will be held during a joint American Diabetes Association (ADA)\/International Pancreas & Islet Transplant Association (IPITA) symposium at the 85th Annual ADA Scientific Sessions taking place June 20-23, 2025 in Chicago, IL. … Continue reading \"Sana Biotechnology Announces Invited Oral Presentation at the 85th Annual American Diabetes Association Scientific Sessions\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/sana-biotechnology-announces-invited-oral-presentation-at-the-85th-annual-american-diabetes-association-scientific-sessions\/","og_site_name":"Market Newsdesk","article_published_time":"2025-06-09T20:43:23+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ2NTYyMyM2OTgyMzc3IzIyMDY2Mzc=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sana-biotechnology-announces-invited-oral-presentation-at-the-85th-annual-american-diabetes-association-scientific-sessions\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sana-biotechnology-announces-invited-oral-presentation-at-the-85th-annual-american-diabetes-association-scientific-sessions\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Sana Biotechnology Announces Invited Oral Presentation at the 85th Annual American Diabetes Association Scientific Sessions","datePublished":"2025-06-09T20:43:23+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sana-biotechnology-announces-invited-oral-presentation-at-the-85th-annual-american-diabetes-association-scientific-sessions\/"},"wordCount":607,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sana-biotechnology-announces-invited-oral-presentation-at-the-85th-annual-american-diabetes-association-scientific-sessions\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ2NTYyMyM2OTgyMzc3IzIyMDY2Mzc=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sana-biotechnology-announces-invited-oral-presentation-at-the-85th-annual-american-diabetes-association-scientific-sessions\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/sana-biotechnology-announces-invited-oral-presentation-at-the-85th-annual-american-diabetes-association-scientific-sessions\/","name":"Sana Biotechnology Announces Invited Oral Presentation at the 85th Annual American Diabetes Association Scientific Sessions - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sana-biotechnology-announces-invited-oral-presentation-at-the-85th-annual-american-diabetes-association-scientific-sessions\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sana-biotechnology-announces-invited-oral-presentation-at-the-85th-annual-american-diabetes-association-scientific-sessions\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ2NTYyMyM2OTgyMzc3IzIyMDY2Mzc=","datePublished":"2025-06-09T20:43:23+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sana-biotechnology-announces-invited-oral-presentation-at-the-85th-annual-american-diabetes-association-scientific-sessions\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/sana-biotechnology-announces-invited-oral-presentation-at-the-85th-annual-american-diabetes-association-scientific-sessions\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sana-biotechnology-announces-invited-oral-presentation-at-the-85th-annual-american-diabetes-association-scientific-sessions\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ2NTYyMyM2OTgyMzc3IzIyMDY2Mzc=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ2NTYyMyM2OTgyMzc3IzIyMDY2Mzc="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sana-biotechnology-announces-invited-oral-presentation-at-the-85th-annual-american-diabetes-association-scientific-sessions\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Sana Biotechnology Announces Invited Oral Presentation at the 85th Annual American Diabetes Association Scientific Sessions"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/858669","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=858669"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/858669\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=858669"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=858669"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=858669"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}